When does the afatinib patent expire?
Specific “afatinib patent expiration dates” depend on the country and which patent is being referenced (primary compound patents, formulation/process patents, and later-life “secondary” patents can all expire at different times). Patent expiry also differs from regulatory exclusivity (for example, data/market exclusivity), which can extend market protection even after a patent expires.
If you tell me the country (e.g., US, EU/UK, Japan, India) and the brand/company you mean (afatinib is marketed as Gilotrif), I can narrow to the relevant expiry date(s) for that jurisdiction and patent set.
How to find the exact expiry date in the US (Gilotrif/afatinib)
In the US, the practical “expiration date” people search for is often the last date a patent listed in the FDA’s Orange Book is expected to block generic competition. That date is commonly reported as a “patent expiry” or “exclusivity” date, and it can include multiple listed patents with different end dates.
To look up the exact date, you generally need:
- The patent number(s) listed for Gilotrif (afatinib) in the Orange Book
- The jurisdiction (US)
- Whether you want the earliest patent expiry or the latest blocking date
What about Europe (including the UK): is there one expiration date?
Europe often has layered protection: national patents plus potential supplementary protection certificates (SPCs) tied to marketing authorizations. That means there may not be a single clean date across all places, even for the same drug and marketing authorization.
For Europe, the key details to confirm are:
- Which country’s patent/SPC coverage you care about
- Whether an SPC was granted and its end date
- Whether other patents (formulation, use, combinations) extend protection
Does exclusivity end at the same time as the last patent?
Not necessarily. Even after patent expiry, regulatory exclusivity (which varies by region and product approval pathway) can limit generic or biosimilar entry until exclusivity ends. The reverse can also happen: patents can outlast certain exclusivity periods.
So searches like “afatinib patent expiration date” often get mixed with “when can generics launch,” which requires checking both patent and exclusivity timelines.
If you’re trying to estimate generic entry, what should you check?
To estimate when generics could enter, you typically need:
- The last (latest) relevant patent expiry date blocking ANDA-style approvals (US context)
- Any Orange Book listings tied to the specific dosage forms
- Any SPC expiry (Europe context)
- Any remaining regulatory exclusivity
Quick clarifying question
Which jurisdiction do you need for the afatinib patent expiration date (US, EU/UK, Japan, India, or another), and do you mean the latest date that blocks generic competition for Gilotrif (afatinib), or the expiry of a specific patent?